$LEXXW News
Last published 3y ago
- 3y agoLEXXLEXXWLexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4ACCESS NewswireKELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms is pleased to announce
- 4y agoABBVELDNLEXXLEXXWLexaria Welcomes Dr. Catherine Turkel to its Board of DirectorsACCESS NewswireKELOWNA, BC / ACCESSWIRE / September 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that Catherine Turkel, PharmD, PhD has joined the board
- 4y agoLEXXLEXXWLexaria Receives New Patent in MexicoACCESS NewswireKELOWNA, BC / ACCESSWIRE / August 31, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recog
- 4y agoLEXXLEXXWLexaria Discusses Valuation Metrics for Biotech IndustryACCESS NewswireThird Party Analysis for Biotech and Pharma Industries KELOWNA, BC / ACCESSWIRE / August 11, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the follow
- 4y agoLEXXLEXXWLexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for HypertensionACCESS NewswireSignificant Milestone Achieved in Commercial Product Development Program Abbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA Pathway KELOWNA, BC / ACCESSWIRE / August 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Co
- 4y agoLEXXLEXXWLexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse EventsACCESS NewswireKELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing with Lexaria's DehydraTECH™-processed cannabi
- 4y agoLEXXLEXXWLexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in JapanACCESS NewswireKELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its exclusive* Japanese Licensee, Premier Wellness Sci
- 4y agoLEXXLEXXWLexaria Files Pre-IND Meeting Request Letter with U.S. FDAACCESS NewswireKELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has successfully filed a pre-Investigational New Drug ("I
- 4y agoLEXXLEXXWLexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese MarketACCESS NewswireMinimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ
- 4y agoLEXXLEXXWLexaria Grants License to Valcon Medical for the European MarketACCESS NewswireContract Manufacturing Organization first in Europe to License DehydraTECH Lexaria will receive milestone fees and royalty payments from product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (th
- 4y agoLEXXLEXXWLexaria Announces 2022 Annual Meeting ResultsACCESS NewswireKELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022
- 4y agoLEXXLEXXWLexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral DrugsACCESS Newswire25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug deliver
- 4y agoLEXXLEXXWLexaria Commences Multi-Week Human Clinical Hypertension StudyACCESS NewswireHYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits This study is designed to enhance Lexaria's probabilities of success with its expected subsequent Investigational New Drug applicati
- 4y agoLEXXLEXXWLexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive ResultsACCESS NewswireData From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration KELOWNA, BC / ACCESSWIRE / April 14,
- 4y agoLEXXLEXXWLexaria Provides Update on Human Nicotine Study NIC-H22-1ACCESS NewswireLexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the
- 4y agoLEXXLEXXWLexaria Begins New Nicotine Formulation Creation and Evaluation ProgramACCESS NewswireKELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC ("Altri
- 4y agoLEXXLEXXWLexaria Begins DehydraTECH-CBD Epilepsy Research ProgramACCESS NewswireProgram EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing. KELOWNA, BC / ACCESSWIRE / March
- 4y agoLEXXLEXXWLexaria Granted Important New Oral Nicotine PatentACCESS NewswireNewest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has b
- 4y agoLEXXLEXXWLexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal StudyACCESS NewswireDehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platform
- 4y agoLEXXLEXXWLexaria Provides Annual Letter From the CEOACCESS NewswireKELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an annual letter from CEO, Chris Bunka and a thorough st
- 4y agoLEXXLEXXWLexaria Comments on Study Examining Cannabinoids and SARS-CoV-2ACCESS Newswire"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery pl
- 4y agoLEXXLEXXWLexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4ACCESS Newswire• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Ind
- 4y agoLEXXLEXXWLexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.ACCESS NewswireKELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the "Co
- 4y agoLEXXLEXXWLexaria's Clinical Hypertension Study HYPER-H21-3 Nears CompletionACCESS NewswireKELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete a
- 4y agoLEXXLEXXWLXRPLexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2ACCESS NewswireResults suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms i
- 5y agoLEXXLEXXWLXRPLexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and DiabetesACCESS NewswireKELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for several new and ongoing DehydraTECHTM applied R&D pro
- 5y agoLEXXLEXXWLXRPLexaria Announces Ambitious New Hypertension Study HYPER-H21-4ACCESS NewswireDehydraTECH-CBD also being evaluated in three other human clinical studies Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Com
- 5y agoLEXXLEXXWLXRPLexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription CannabidiolACCESS NewswireNew study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"
- 5y agoLEXXLEXXWLXRPLexaria's Technology Proven to Deliver Oral THC More EffectivelyACCESS NewswireDehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in d
- 5y agoLEXXLEXXWLXRPLexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding ResultsACCESS NewswireDehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "
- 5y agoLEXXLEXXWLXRPLexaria to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceACCESS NewswireKELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that Chairman & CEO Chris Bunka will present at the 23rd Annua
- 5y agoLEXXLEXXWLXRPLexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for HypertensionACCESS NewswirePositive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery plat
- 5y agoLEXXLEXXWLXRPLexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory PeriodACCESS NewswireHuman Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Comp
- 5y agoLEXXLEXXWLXRPLexaria's DehydraTECH-CBD Lowers Blood PressureACCESS NewswireHuman Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Le
- 5y agoLEXXLEXXWLXRPDehydraTECH-Enabled Consumer Products Now Available in Over 7,000 StoresACCESS NewswireLexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator i
- 5y agoLEXXLEXXWLXRPLexaria Completes Dosing in Human Clinical Study HYPER-H21-2ACCESS NewswireAdditionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that
- 5y agoLEXXLEXXWLXRPLexaria Receives US$3,817,643 From Warrant ExercisesACCESS NewswireKELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the receipt of US$3,817,643 from the exercise of share purc
- 5y agoLEXXLEXXWLXRPLexaria Summarizes Successful Antiviral Drug Studies and Ongoing StrategyACCESS NewswireAll objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platf
- 5y agoLEXXLEXXWLXRPLexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3ACCESS NewswirePossible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms
- 5y agoLEXXLEXXWLXRPLexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research CouncilACCESS NewswireVIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is
- 5y agoLEXXLEXXWLXRPLexaria Receives Patent Protection in JapanACCESS NewswireNew patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delive
- 5y agoLEXXLEXXWLXRPLexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital MarketsACCESS NewswireKELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request
- 5y agoLEXXLXRPLEXXWLexaria Announces 2021 Annual Meeting ResultsACCESS NewswireKELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On Jun
- 5y agoLEXXLXRPLEXXWLexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral DrugsACCESS NewswireDehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria")
- 5y agoLEXXLXRPLEXXWLexaria Provides Progress Report on Six R&D ProgramsACCESS NewswireAll studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strat
- 5y agoLEXXLXRPLEXXWLexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1ACCESS NewswireDosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria's Patented Technology for Hypertension Relief Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation Second Human Clinical Study, Hyper-H21-2, To
- 5y agoLEXXLXRPLEXXWLexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 VirusACCESS NewswireKELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were ef
- 5y agoLEXXLXRPLEXXWLexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results EverACCESS NewswireNew formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company"
- 5y agoLEXXLXRPLEXXWLexaria Strengthens Its International Patent Portfolio to 19 Patents GrantedACCESS NewswireNew patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Le
- 5y agoLEXXLEXXWLXRPLexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ETACCESS NewswireLexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE / May 7, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(N